FR EN MAIN NAVIGATION COMPANY SCIENCE PRODUCTS PARTNERING INVESTORS MEDIA CAREERS LACUTAMAB PROPRIETARY PROGRAM | PHASE 2 | CUTANEOUS T-CELL LYMPHOMA Home Products Lacutamab Lacutamab (IPH4102) is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, which is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease. This group of rare cutaneous lymphomas of T lymphocytes has a poor prognosis with few efficacious and safe therapeutic options at advanced stages. KIR3DL2 is an inhibitory receptor of the KIR family, expressed by approximately 65% of patients across all CTCL subtypes and expressed by up to 90% of patients with certain aggressive CTCL subtypes, in particular, Sézary syndrome. It is expressed by up to 50% of patients with peripheral T-cell lymphoma (PTCL). It has a restricted expression on normal tissues. Mechanism of action Clinical development Publications, posters and presentations View publications Main menu Pipeline overview Clinical trials ------------------ Lacutamab Monalizumab Avdoralimab IPH5201 IPH5301 IPH6101 IPH62 LATEST NEWS ON LACUTAMAB Innate Pharma Third Quarter 2021 Report November 16, 2021 Innate Pharma Reports First Half 2021 Financial Results and Business Update September 15, 2021 Innate Pharma Presents Preliminary Data from TELLOMAK Trial Showing Clinical Response for Lacutamab in Mycosis Fungoides June 22, 2021 All press releases Footer Contact Location Legal Info Terms of use Privacy Notice Cookies notice General Conditions of Purchase Search Search Follow us Stay in touch Subscribe to our newsletter Contact us Location 117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30 Innate Pharma, Inc. 2273 Research Boulevard, Suite 350 Rockville, MD 20850, USA